Biomarkers in early-stage colorectal cancer: Ready for prime time?

Digestive Diseases

Volumn 30, Issue SUPPL.2, 2012, Pages 27-33

  Church, David ^a   Midgley, Rachel ^a   Kerr, David ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Biomarkers; Colorectal cancer; Microsatellite instability

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; FLUOROURACIL; K RAS PROTEIN; TUMOR MARKER;

CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CHROMOSOME 18Q; CHROMOSOME DELETION; COLORECTAL CANCER; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DNA MICROARRAY; DRUG EFFICACY; DRUG RESPONSE; EARLY CANCER; GENE EXPRESSION PROFILING; HUMAN; MICROARRAY ANALYSIS; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MISMATCH REPAIR; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; SURVIVAL TIME;

CHROMOSOMAL INSTABILITY; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 18; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; GENE EXPRESSION PROFILING; HUMANS; MICROSATELLITE INSTABILITY; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870835842     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000341890     Document Type: Conference Paper

References (46)

1. Ferlay J, Shin H-R, Bray F, Forman D,Mathers C, Parkin DM: Estimates of worldwideburden of cancer in 2008: GLOBOCAN2008. Int J Cancer 2010; 127: 2893-2917.
2. Gray R, Barnwell J, McConkey C, Hills RK,Williams NS, et al; Quasar CollaborativeGroup: Adjuvant chemotherapy versus observationin patients with colorectal cancer: A randomised study. Lancet 2007; 370: 2020-2029.
3. O'Connell JB, Maggard MA, Ko CY: Coloncancer survival rates with the new AmericanJoint Committee on Cancer sixth editionstaging. J Natl Cancer Inst 2004; 96: 1420-1425.
4. Midgley RS, Church D, Kerr DJ: The emergenceof 'omics for the management ofcolorectal cancer. Curr Opin Oncol 2011; 23:410-414.
5. Anwar S, Frayling IM, Scott NA, Carlson GL:Systematic review of genetic influences onthe prognosis of colorectal cancer. Br J Surg2004; 91: 1275-1291.
6. Munro AJ, Lain S, Lane DP: P53 abnormalitiesand outcomes in colorectal cancer: a systematicreview. Br J Cancer 2005; 92: 434-444.
7. Simon RM, Paik S, Hayes DF: Use of archivedspecimens in evaluation of prognostic andpredictive biomarkers. J Natl Cancer Inst2009; 101: 1446-1452.
8. Walther A, Houlston R, Tomlinson I: Associationbetween chromosomal instabilityand prognosis in colorectal cancer: a metaanalysis.Gut 2008; 57: 941-950.
9. Lee AJX, Endesfelder D, Rowan AJ, WaltherA, Birkbak NJ, Futreal PA, et al: Chromosomalinstability confers intrinsic multidrugresistance. Cancer Res 2011; 71: 1858-1870.
10. Vogelstein B, Fearon ER, Hamilton SR, KernSE, Preisinger AC, Leppert M, et al: Geneticalterations during colorectal-tumor development.N Engl J Med 1988; 319: 525-532.
11. Popat S, Houlston RS: A systematic reviewand meta-analysis of the relationship betweenchromosome 18q genotype, DCC statusand colorectal cancer prognosis. Eur JCancer 2005; 41: 2060-2070.
12. Downward J: Targeting RAS signalling pathwaysin cancer therapy. Nat Rev Cancer2003; 3: 11-22.
13. Maughan TS, Adams RA, Smith CG, MeadeAM, Seymour MT, Wilson RH, et al: Additionof cetuximab to oxaliplatin-based firstlinecombination chemotherapy for treatmentof advanced colorectal cancer: resultsof the randomised phase 3 MRC COIN trial.Lancet 2011; 377: 2103-2114.
14. Dahabreh IJ, Terasawa T, Castaldi PJ, TrikalinosTA: Systematic review: anti-epidermalgrowth factor receptor treatment effectmodification by KRAS mutations in advancedcolorectal cancer. Ann Intern Med2011; 154: 37-49.
15. Allegra CJ, Jessup JM, Somerfield MR, HamiltonSR, Hammond EH, Hayes DF, et al:American Society of Clinical Oncology provisionalclinical opinion: testing for KRASgene mutations in patients with metastaticcolorectal carcinoma to predict responseto anti-epidermal growth factor receptormonoclonal antibody therapy. J Clin Oncol2009; 27: 2091-2096.
16. Linardou H, Dahabreh IJ, Kanaloupiti D, SiannisF, Bafaloukos D, Kosmidis P, et al: Assessmentof somatic k-RAS mutations as amechanism associated with resistance toEGFR-targeted agents: a systematic reviewand meta-analysis of studies in advancednon-small-cell lung cancer and metastaticcolorectal cancer. Lancet Oncol 2008; 9: 962-972.
17. Roth AD, Tejpar S, Delorenzi M, Yan P, FioccaR, Klingbiel D, et al: Prognostic role ofKRAS and BRAF in stage II and III resectedcolon cancer: results of the translationalstudy on the PETACC-3, EORTC 40993,SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474.
18. Parsons R, Myeroff LL, Liu B, Willson JK,Markowitz SD, Kinzler KW, et al: Microsatelliteinstability and mutations of the transforminggrowth factor beta type II receptorgene in colorectal cancer. Cancer Res 1995;55: 5548-5550.
19. Souza RF, Appel R, Yin J, Wang S, SmolinskiKN, Abraham JM, et al: Microsatellite instabilityin the insulin-like growth factor II receptorgene in gastrointestinal tumours. NatGenet 1996; 14: 255-257.
20. Rampino N, Yamamoto H, Ionov Y, Li Y,Sawai H, Reed JC, et al: Somatic frameshiftmutations in the BAX gene in colon cancersof the microsatellite mutator phenotype. Science1997; 275: 967-969.
21. Rajagopalan H, Bardelli A, Lengauer C,Kinzler KW, Vogelstein B, Velculescu VE:Tumorigenesis: RAF/RAS oncogenes andmismatch-repair status. Nature 2002; 418:934.
22. Herman JG, Umar A, Polyak K, Graff JR,Ahuja N, Issa JP, et al: Incidence and functionalconsequences of hMLH1 promoterhypermethylation in colorectal carcinoma.Proc Natl Acad Sci USA 1998; 95: 6870-6875.
23. Risio M, Reato G, di Celle PF, Fizzotti M,Rossini FP, Foà R: Microsatellite instabilityis associated with the histological features ofthe tumor in nonfamilial colorectal cancer.Cancer Res 1996; 56: 5470-5474.
24. Salahshor S, Kressner U, Fischer H, LindmarkG, Glimelius B, Påhlman L, et al: Microsatelliteinstability in sporadic colorectalcancer is not an independent prognostic factor.Br J Cancer 1999; 81: 190-193.
25. Barratt PL, Seymour MT, Stenning SP, GeorgiadesI, Walker C, Birbeck K, et al: DNAmarkers predicting benefit from adjuvantfluorouracil in patients with colon cancer: A molecular study. Lancet 2002; 360: 1381-1391.
26. Halling KC, French AJ, McDonnell SK, BurgartLJ, Schaid DJ, Peterson BJ, et al: Microsatelliteinstability and 8p allelic imbalancein stage B2 and C colorectal cancers. J NatlCancer Inst 1999; 91: 1295-1303.
27. Watanabe T, Wu TT, Catalano PJ, Ueki T, SatrianoR, Haller DG, et al: Molecular predictorsof survival after adjuvant chemotherapyfor colon cancer. N Engl J Med 2001; 344:1196-1206.
28. Bertagnolli MM, Redston M, Compton CC,Niedzwiecki D, Mayer RJ, Goldberg RM, etal: Microsatellite instability and loss of heterozygosityat chromosomal location 18q:prospective evaluation of biomarkers forstages II and III colon cancer- A study ofCALGB 9581 and 89803. J Clin Oncol 2011;29: 3153-3162.
29. Sinicrope FA, Foster NR, Thibodeau SN,Marsoni S, Monges G, Labianca R, et al:DNA mismatch repair status and colon cancerrecurrence and survival in clinical trialsof 5-fluorouracil-based adjuvant therapy. JNatl Cancer Inst 2011; 103: 863-875.
30. Sargent DJ, Marsoni S, Monges G, ThibodeauSN, Labianca R, Hamilton SR, et al: Defectivemismatch repair as a predictive marker forlack of efficacy of fluorouracil-based adjuvanttherapy in colon cancer. J Clin Oncol2010; 28: 3219-3226.
31. Popat S, Hubner R, Houlston RS: Systematicreview of microsatellite instability andcolorectal cancer prognosis. J Clin Oncol2005; 23: 609-618.
32. Carethers JM, Chauhan DP, Fink D, NebelS, Bresalier RS, Howell SB, et al: Mismatchrepair proficiency and in vitro response to5-fluorouracil. Gastroenterology 1999; 117:123-131.
33. Ribic CM, Sargent DJ, Moore MJ, ThibodeauSN, French AJ, Goldberg RM, et al: Tumormicrosatellite-instability status as a predictorof benefit from fluorouracil-based adjuvantchemotherapy for colon cancer. N EnglJ Med 2003; 349: 247-257.
34. Carethers JM, Smith EJ, Behling CA, NguyenL, Tajima A, Doctolero RT, et al: Use of 5-fluorouraciland survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology2004; 126: 394-401.
35. Storojeva I, Boulay J-L, Heinimann K, BallabeniP, Terracciano L, Laffer U, et al: Prognosticand predictive relevance of microsatelliteinstability in colorectal cancer. OncolRep 2005; 14: 241-249.
36. Guastadisegni C, Colafranceschi M, OttiniL, Dogliotti E: Microsatellite instability as amarker of prognosis and response to therapy: A meta-analysis of colorectal cancer survivaldata. Eur J Cancer 2010; 46: 2788-2798.
37. Guetz Des G, Schischmanoff O, Nicolas P,Perret G-Y, Morere J-F, Uzzan B: Does microsatelliteinstability predict the efficacyof adjuvant chemotherapy in colorectal cancer?A systematic review with meta-analysis.Eur J Cancer 2009; 45: 1890-1896.
38. Kim GP, Colangelo LH, Wieand HS, Paik S,Kirsch IR, Wolmark N, et al: Prognostic andpredictive roles of high-degree microsatelliteinstability in colon cancer: a National CancerInstitute-National Surgical AdjuvantBreast and Bowel Project CollaborativeStudy. J Clin Oncol 2007; 25: 767-772.
39. Wang Y, Jatkoe T, Zhang Y, Mutch MG, TalantovD, Jiang J, et al: Gene expression profilesand molecular markers to predict recurrenceof Dukes' B colon cancer. J Clin Oncol2004; 22: 1564-1571.
40. Jiang Y, Casey G, Lavery IC, Zhang Y, TalantovD, Martin-McGreevy M, et al: Developmentof a clinically feasible molecular assayto predict recurrence of stage II colon cancer.J Mol Diagn 2008; 10: 346-354.
41. Barrier A, Lemoine A, Boelle P-Y, Tse C,Brault D, Chiappini F, et al: Colon cancerprognosis prediction by gene expression profiling.Oncogene 2005; 24: 6155-6164.
42. Barrier A, Boelle P-Y, Roser F, Gregg J, Tse C,Brault D, et al: Stage II colon cancer prognosisprediction by tumor gene expression profiling.J Clin Oncol 2006; 24: 4685-4691.
43. Eschrich S, Yang I, Bloom G, Kwong KY,Boulware D, Cantor A, et al: Molecular stagingfor survival prediction of colorectal cancerpatients. J Clin Oncol 2005; 23: 3526-3535.
44. Salazar R, Roepman P, Capella G, Moreno V,Simon I, Dreezen C, et al: Gene expressionsignature to improve prognosis prediction ofstage II and III colorectal cancer. J Clin Oncol2011; 29: 17-24.
45. O'Connell MJ, Lavery I, Yothers G, Paik S,Clark-Langone KM, Lopatin M, et al: Relationshipbetween tumor gene expression andrecurrence in four independent studies ofpatients with stage II/III colon cancer treatedwith surgery alone or surgery plus adjuvantfluorouracil plus leucovorin. J Clin Oncol2010; 28: 3937-3944.
46. Kerr DG, Quirke R, Watson P, et al: A quantitativemultigene RT-PCR assay for predictionof recurrence in stage II colon cancer:Selection of the genes in four large studiesand results of the independent, prospectivelydesigned QUASAR validation study. J ClinOncol 2009; 27(15s suppl):abstract 4000.